Calyxha is a company headquartered in Germany.
Calyxha is a private biotechnology company developing novel small-molecule anti-inflammatory drugs targeting multiple inflammatory diseases. Its lead candidate, CAL-4, is being developed as a potential corticosteroid alternative for asthma and is in preclinical development with planned clinical entry by 2024.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.